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Model systems provide an invaluable tool for investigating the molecular mechanisms underlying the NCLs, devastating neurodegenerative
disorders that affect the relatively inaccessible tissues of the central nervous system. These models have enabled the assessment of behavioural,
pathological, cellular, and molecular abnormalities, and also allow for development and evaluation of novel therapies. This review highlights the
relative advantages of the two available small vertebrate species, the mouse and zebrafish, in modelling NCL disease, summarising how these have
been useful in NCL research and their potential for the development and testing of prospective disease treatments. A panel of mouse mutants is
available representing all the cloned NCL gene disorders (Cathepsin D, CLN1, CLN2, CLN3, CLN5, CLN6, CLN8). These NCL mice all have
progressive neurodegenerative phenotypes that closely resemble the pathology of human NCL. The analysis of these models has highlighted several
novel aspects underlying NCL pathogenesis including the selective nature of neurodegeneration, evidence for glial responses that precede neuronal
loss and identification of the thalamus as an important pathological target early in disease progression. Studies in mice have also highlighted an
unexpected heterogeneity underlying NCL phenotypes, and novel potential NCL-like mouse models have been described including mice with
mutations in cathepsins, CLC chloride channels, and other lysosome-related genes. These new models are likely to provide significant new
information on the spectrum of NCL disease. Information on NCL mice is available in the NCL Mouse Model Database (http://www.ucl.ac.uk/ncl-
models/). There are homologs of most of the NCL genes in zebrafish, and NCL zebrafish models are currently in development. This model system
provides additional advantages to those provided by NCL mouse models including high-throughput mutational, pharmacogenetic and therapeutic
technique analyses. Mouse and zebrafish models are an important shared resource for NCL research, offering a unique possibility to dissect disease
mechanisms and to develop therapeutic approaches.
© 2006 Elsevier B.V. All rights reserved.Keywords: Mouse; Model; Neuronal ceroid lipofuscinosis; Batten disease; Zebrafish; Neurodegeneration1. Introduction
The study of disease mechanisms in the NCLs, as for other
neurodegenerative disorders, presents significant challenges.
This group of clinically related storage disorders is defined by
the progressive accumulation of intracellular protein aggregates
and the dysfunction and death of specific populations of
neurons within the central nervous system. In the last 10 years
the identification of distinct NCL disease-causing mutations has⁎ Corresponding author.
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doi:10.1016/j.bbadis.2006.08.002boosted studies into the pathogenesis of these disorders [1], with
the introduction of new molecular methods and biomarkers to
investigate the underlying disease mechanisms. As described
elsewhere in this issue, the discovery of NCL genes has also
facilitated progress towards the development of gene transfer-
based therapeutic strategies for infantile and late-infantile NCL,
although functional replacement for variant late-infantile and
juvenile NCL subtypes which involve dysfunction of mem-
brane-bound proteins remains a more distant prospect.
The long-term hope arising from molecular biochemical
studies is that once the disease biology is more fully understood,
it will be possible to develop mechanism-based treatments that
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of the NCLs and move towards achieving this goal, it has been
necessary to model the diseases in non-human systems. The
ability to dissect the successive stages of disease progression in
animal models provides significant experimental advantages
over the human material which can only give a static snapshot
of the disease at its endstage in post-mortem material. In
contrast, model systems provide direct access to all tissues
throughout the disease course which can be monitored from the
early developmental stages up to death. These models also
provide a controlled system for systematic assessment of
therapeutic approaches that is not possible in NCL patients.
There are a variety of model organisms available, each with
distinct advantages and limitations. As reviewed elsewhere in
this issue, several non-vertebrate models of NCL exist or are in
development [2–7]. However, vertebrate models offer the best
opportunity for defining landmarks of disease progression and
for understanding the functional consequences of gene
mutation. Vertebrate NCL models are also required for
evaluation of new treatment regimes and will be vital for
paving the way towards clinical trials, with both large vertebrate
(covered elsewhere in this issue) and small vertebrate NCL
model systems available. In this review we will summarise the
advantages of the two available small vertebrate species, mice
and zebrafish, their use in modelling NCL, and recent advances
in their analysis. We will also discuss a series of common
hypotheses about NCL neuropathogenesis that have arisen from
the study of these NCL models.
2. NCL mouse models
Mice are a key organism for genetically modelling human
disease owing to the extent of their functional cross-species
conservation, and mouse models of human disease provide
critical information for understanding disease pathogenesis
and effectively targeting potential treatments [8]. Mouse
models of neurological disease have arisen as spontaneous or
‘naturally-occurring’ mutant strains, or have been generated
via large-scale random mutagenesis programs [9] and by
genetic modification techniques [10]. Furthermore, refinement
of the traditional ‘knock-out’ genetic modification technology
has allowed the exact replication of specific human mutations
by related ‘knock-in’ strategies. Aided by complete sequenc-
ing of the mouse genome [11], mice can now be genetically
engineered to carry mutations in specific disease-related genes
with relative ease. Many useful neurological mouse mutants
have been characterized by a wide range of methods, and as
more become available the emphasis has increased on
development and assessment of testable phenotypic beha-
viours that mirror the symptoms of human neurological
disease [12,13].
Mouse models have played a vital role in recent advances in
understanding the biology of the NCLs. A set of gene-specific
NCL mouse models is now available for each of the genetically
characterized human NCL subtypes of childhood (Table 1) and
descriptions of all mouse models maybe found in the NCL
Mouse Model Database (http://www.ucl.ac.uk/ncl-models/). Inaddition to two spontaneous mutant mice [14,15], a series of
genetically engineered mutant mice are now available.
NCL mouse models have been created in a number of ways,
by replacement of part of the NCL gene by an insertion
mutation involving a selectable marker, either with [16,17] or
without [18–21] an additional amino acid mutation in the
coding region. Alternatively, more subtle deletions have been
generated using cre-lox technology in order to leave no portion
of the selection cassette present in the targeted allele [22,23].
Using this approach a genetically engineered knock-in mouse
has been generated which mimics the major 1.02 Kb mutation
in CLN3 that is found in most juvenile-onset NCL patients
[23]. As outlined below, each of the NCL mouse models
exhibit certain key features of human NCL including
autofluorescent intracellular storage, and progressive neurode-
generative changes.
In addition to these defined models of NCL, several other
mouse models exist with phenotypic features that resemble the
NCLs. As such, these mice may represent forms of NCL that do
not have a human correlate at present, until corresponding
mutations are found in NCL patients. These putative NCL
models include mice deficient for cathepsin F, and mice double
deficient for both cathepsin B and L, all of which are all
lysosomal cysteine proteases [24,25]; mice deficient for the
CLC chloride channel family members CLC-3 [26–28] and
CLC-7 [29,30]which function in the endocytic system and
synaptic vesicles; and mice deficient for palmitoyl protein
thioesterase 2 (PPT2) [16,31] which is a lysosomal thioesterase
enzyme functionally related to the infantile NCL protein PPT1.
Despite certain similarities to an NCL-like phenotype in each of
these mice, it remains to be seen whether these mice truly
represent models of new forms of NCL.
3. Infantile NCL, CLN1: Ppt1 mutant mice
Two mouse models of infantile NCL have been generated
in which Ppt1 enzyme activity is abolished due to targeted
gene disruption, either by insertion mutation into exon 9 [16],
or complete deletion of exon 4, of the Ppt1 gene [22] (Table
1). Both mutations have been studied in the same mixed
strain background and their phenotypes are broadly similar,
displaying intracellular accumulation of storage material with
a characteristic INCL granular osmiophilic deposit (GROD)
appearance and an early onset progressive neurodegenerative
disorder leading to premature death from 4 to 5 months of
age onwards. These mice also exhibit signs of neurological
abnormalities in the form of abnormal clasping behaviour in a
tail suspension test by 2 months of age [16] and the
development of motor deficits and spontaneous seizures by
4–5 months. Visual defects are also apparent in both models
of INCL, occurring in the Ppt1Δex4 knock-out model as early
as 14 weeks, measured behaviourally [22], and from 2 months
onwards in the Ppt1 (ex 9 insertion) knock-out model, mea-
sured by ERG recordings [32].
Severe neurodegeneration is readily apparent in the CNS of
Ppt1-deficient mice by histological methods. In the Ppt1Δex4
knock-out model, close to end-stage at 6 months there is a gross
Table 1
Selected NCL mouse models
Human gene Mouse model Genetic mutation Molecular defect Published strains Onset of
neurological signs
Retinal
involvement
Mortality Original reference
Congenital NCL
Cathepsin D CTSD Ctsd−/− knockout Exon 4 replacement
insertion.
No enzyme
activity
C57BL/6−129/Ola From 3 weeks + At 25–27 days [18]
Infantile NCL
Palmitoyl protein
thioesterase 1
(PPT1, CLN1)
Ppt1−/− knockout Exon 9 insertion+
termination codon
at Val281
No enzyme
activity
C57BL/6J-129/Sv
and C57BL/6J
congenic [31]
From 2 months + From 5 months.
No survival > 10 months
[16]
Palmitoyl protein
thioesterase 1
(PPT1, CLN1)
Ppt1Δex4 knockout Exon 4 deletion No enzyme
activity
C57BL/6J-129/Sv From 4 months + Death on average
by 6.5 months
[22]
Late-infantile NCL and variant forms
Tripeptidyl peptidase 1
(TTP1, CLN2)
Tpp1 neoinsArg446His
knockout
Intron 11
insertion+exon 11
Arg466His missense
No enzyme
activity
C57BL/6J-129/Sv
and 129/Sv inbred
From 9 weeks n.d. From 2.5 months.
No survival > 6 months
[17]
CLN5 Cln5−/− knockout Exon 3 replacement
insertion
Deleted
mRNA
C57BL/6J-129/Sv No motor or
seizure phenotypes
by 8 months
From 13 weeks n.d. [21]
CLN6 Cln6nclf spontaneous
mutant
c.316insC single base
insertion
Frameshift
after Pro102
C57BL6-C57BL/
10- C3HeB/FeJLe
From 8 months + Death by 12 months [15,47,48]
CLN8 Cln8mnd spontaneous
mutant
c.267–268insC
single base insertion
Frameshift
after Val89
C57BL/6-KB2 and
C57BL/6-KB2-
AKR/J [112]
From 4 months + Death by 10–12 months [14,46]
Juvenile NCL
CLN3 Cln3−/− knockout Exons 1–6
replacement insertion
Deleted
mRNA and
absent protein [59]
C57BL/6J-129/Sv
and 129/Sv inbred [58]
From 16 months Retinal
function preserved.
Defective optic nerve
from 6 moths [60]
No survival >20 months [19]
CLN3 Cln3Δex7/8 knock-in Exons 7–8 deletion Deleted mRNA+
alternatively
spliced mRNAs
129/Sv-CD1 Present at
10–12 months
+ From 7 months. 80% survival
by 10–12 months
[23]
CLN3 Cln3 knockout Exons 7–8
replacement insertion
Deleted mRNA+
alternatively
spliced mRNAs
C57BL/6J-129/Sv and
C57BL/6J
congenic [54]
From 14 weeks
in congenic
n.d. n.d. [20]
All frameshift and mRNA deletion mutations are predicted to cause premature protein truncation. GROD, CVand FP refer respectively to granular osmiophilic deposits, curvilinear profiles and fingerprint bodies which
are terms used to describe the storage bodies associated with human NCL forms. Additional references and descriptions of these NCL mouse model phenotypes are presented in [52] and at http://www.ucl.ac.uk/
ncl-models/. Additional NCL-like mouse models not included in the table are described in the text.
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GABAergic neuronal loss in the cortex and cerebellum [22].
There is similar GABAergic cell loss observed in the hippo-
campus and cerebellum at 6 months in Ppt1 (ex 9 insertion)
knock-out mice [16]. This model has been studied in more detail
both pathologically [32–35] and behaviourally [35]. The CNS
deficits in the Ppt1 (ex 9 insertion) knock-out model are striking
at 7 months of age, with marked neuron loss accompanied by a
profound glial response. Nevertheless, this model still displays a
remarkable selectivity for which neuron populations and CNS
regions are most affected [33]. Regional atrophy is not confined
to the cortex, but also involves subcortical structures, with the
thalamus being the most affected CNS region in this mouse
model.
As discussed below, several examples of selective neuronal
vulnerability are apparent in Ppt1-deficient mice [33]. Discov-
ering the molecular basis for such marked differences in cell
vulnerability will be of critical importance in understanding
NCL pathogenesis. Nevertheless, the detailed landmarks
available from the Ppt1 knock-out mice have already been
used to judge the therapeutic efficacy of gene transfer methods
[32,34,35] as described elsewhere in this issue, and are being
used to test other approaches including transplanted human
neural stem cell lines. After initial studies in Ppt1 knock-out
mice, a USA-based biotech company, StemCells, Inc., has
received clearance from the U.S. Food and Drug Administration
(FDA) for Phase I clinical trials to investigate the safety and
preliminary efficacy of a neural stem cell line in the treatment of
infantile and late-infantile NCL in affected patients (http://www.
stemcellsinc.com/clinicaltrials/clinicaltrials.html).
An exploration of neuronal deficits arising from loss of Ppt1
function has been initiated at the cellular level by establishment
of primary cortical neuron cultures derived from Ppt1 (ex 9
insertion) knock-out mice [36]. Although tests of synaptic
transmission and density revealed no alterations, there was a
reduction in the number of synaptic vesicles present in synapses,
a defect which could represent an initial stage of neuronal
dysfunction and may underlie the INCL-related seizure
phenotype [36].
Ppt1 (ex 9 insertion) knock-out mice have also been used for
an investigation of the mechanisms of neuronal death, following
the observation of altered ultrastructure in brain tissues. These
pathological changes included altered endoplasmic reticulum
(ER) morphology and an accumulation of apoptotic bodies
towards the end-stage of disease [37]. This morphology was
associated with activation of the unfolded protein response
(UPR) in Ppt1-deficient cells and of apoptosis mediated via
caspases 3 and 12, suggesting that alleviation of ER stress could
potentially provide a therapeutic route for INCL [37].
4. Classic late-infantile NCL, CLN2: Tpp1 mutant mice
A mouse model has been created in which Tpp1 enzyme
activity is abolished by gene targeting (Table 1), recapitulating
the features of classic late-infantile NCL with accumulation of
storage material with classic curvilinear profile ultrastructure
and a rapid neurodegenerative phenotype [17]. This mouseexhibits the earliest onset and most pronounced neurodegener-
ative phenotype of any NCL mice, although detailed informa-
tion about how this phenotype arises is not yet available.
Nevertheless, it is apparent that degeneration is pronounced
within the thalamocortical system of Tpp1-deficient mice, with
marked effects within the cerebellum [17].
Comparison between animals on different strain back-
grounds or housed in different animal facilities is difficult, but
it is intriguing that this mutant appears to be more severely
affected than either of the Ppt1 knock-out mice. Increasingly
severe tremors are detectable in Tpp1-deficient mice from
7 weeks of age and by 9 weeks there is a significant reduction in
neurological and motor skills which decline rapidly with age,
with no mutants surviving beyond 6 months. This relatively
severe phenotype may be related to the specific mutation
present in this mouse model which is not an exact replica of a
human mutation, being an insertion of the CLN2-specific
Arg447His missense mutation [38] into the Tpp1 protein in
addition to a large intronic insertion. Preliminary data suggests
that changing the mutation from a mixed C57BL/6J-129/Sv
strain onto inbred 129/Sv strain reduces mortality [17],
indicating the involvement of modifier genes in the LINCL
phenotype, as has been noted previously in many examples
from NCL patients and mouse models [17,39–41]. Tpp1-
deficient mice have recently been used in an initial attempt at
Tpp1 gene transfer which achieved a significant reduction in
storage material [42], although it remains to be seen if this
approach also has beneficial effects upon neurodegenerative,
reactive or behavioural phenotypes.
5. Variant late-infantile NCL, CLN5: Cln5−/− knock-out
mutant mice
A knock-out mouse model for Finnish variant late-infantile
NCL (vLINCLFin/CLN5) has been created by gene targeting
using the insertion of a neomycin selectable marker to disrupt
exon 3 [21]. This mutation gives rise to a deleted mRNA
species in these mutant mice resulting in a frameshift mutation
with a premature stop codon, predicted to result in a
prematurely truncated Cln5 protein [21]. This is proposed to
be quite close in effect to a particular human CLN5 mutation,
Glu253Stop [43].
Cln5−/− mice display features of the disease including
accumulation of storage material with an appropriate ultrastruc-
ture and an NCL-type neurological phenotype [21]. Progressive
loss of vision is the leading symptom in Cln5−/− mice, but apart
from the presence of severe visual defects by 5 months of age,
no other obvious clinical symptoms such as seizures or motor
deficits were observed up to 8 months of age and this appears to
be a comparatively mildly affected mutant. The phenotype is
strikingly different from that of Ppt1 and Tpp1 knock-out mice,
and is in agreement with the broad late-infantile disease
spectrum and the milder clinical phenotype of vLINCLFin/
CLN5 patients compared to INCL and CLN2 patients [1]. Of
the four cloned NCLs which are not due to enzyme defects,
CLN5 could be of particular interest for development of
therapeutic approaches since it exists as a soluble gene product
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this avenue of research.
Initial analysis of neuropathological changes in Cln5−/−
mice revealed a progressive loss of GABAergic interneurons in
several regions including the cerebral cortex, hippocampus,
midbrain and cerebellum [21]. Although this loss of GABAer-
gic and other neuron populations occurs with a relatively late
onset, Cln5−/− mice appear to display a relatively pronounced
neuroinflammatory response early in disease progression.
Microarrays reveal an upregulation of several immune response
genes [21], and supporting immunohistochemical evidence has
also been collected (von Schantz et al., unpublished
observations).
6. Variant late-infantile NCL, CLN6 and CLN8: Cln6nclf
and Cln8mnd mutant mice
Two naturally occurring mouse mutants represent models for
variant late-infantile NCL (vLINCL) subtypes CLN6 and CLN8
since they carry mutations that arose spontaneously in the
murine homologs of these NCL genes (Table 1). The Cln8mnd
mouse was originally described as a spontaneous mutant model
of motor neuron disease due to its neurodegenerative pheno-
type, but was suggested to be an NCL model before the
underlying Cln8 gene mutation was known [14,46]. Similarly,
the Cln6nclf mouse was proposed to be an NCL model prior to
the human gene mutation being identified [15]. It was
subsequently established that the Cln6nclf and Cln8mnd mice
do in fact bear mutations in the murine homologs of the CLN6
and CLN8 genes respectively, which are responsible for human
variant late-infantile NCL forms [47–49]. There is also the well-
studied South Hampshire sheep model of CLN6 [50,51],
described elsewhere in this issue.
The Cln6nclf mutation is shared with vLINCL patients from
Costa Rica and therefore like the Cln3Δex7/8 knock-in mice, this
is a genetically accurate model with respect to human NCL
disease. With the caveat that it is a comparison between species,
the Cln8mnd mouse has a phenotype that is closer to the more
severe clinical course recorded in a set of CLN8 patients from
Turkey [52] than to other CLN8 (Northern epilepsy type)
patients that present with a much less severe clinical course
[47]. Such differences in disease presentation in human CLN8
patients have been ascribed to their different inherited
mutations. The severe protein truncation mutation present in
the Cln8mnd mouse is predicted to completely abolish its
function and this effect on protein function is closer to that of
the Turkish CLN8 mutation.
As reviewed previously, both CLn6nclf and CLn8mnd mice
show progressive neurodegenerative phenotypes with accumu-
lation of autofluorescent storage material [46,53]. Identifica-
tion of the causative gene mutations in CLn6nclf and CLn8mnd
mice raises their importance and should prompt a re-evaluation
of these mice as genetically accurate models of late-infantile
NCL variant forms. For example, interest in the retinal
pathology of Cln8mnd mice has recently been renewed with a
view to establishing clinically relevant neurodegenerative signs
[54,55].7. Juvenile NCL, CLN3: Cln3−/− knock-out and Cln3Δex7/8
knock-in mutant mice
Three mouse models of juvenile onset NCL have been
created by different gene targeting strategies: two different Cln3
knock-out mice [19,20] and one Cln3 knock-in mouse [23]. The
knock-out mice were made by insertion mutation using the
neomycin selectable marker to disrupt the Cln3 gene by
replacement of exons 1–6 [19], or of exons 7–8 [20]. A more
subtle mutation in the knock-in mouse was created using cre-lox
technology, such that Cln3 exons 7 and 8 were replaced by a
single loxP site that was left in the intronic sequence between
exons 6 and 9 [23], thereby exactly mimicking the major CLN3
1.02 Kb deletion carried by the majority of JNCL patients,
which completely removes exons 7 and 8 [56].
These three mouse models each recapitulate the storage
phenotype of JNCL and a variety of appropriate neurodegen-
erative features [53]. It is not yet clear which will prove to be the
most accurate model since these mice were bred on different
strain backgrounds that may have a significant effect on their
phenotypes. For example, some of the Cln3Δex7/8 knock-in
mice which had a mixed 129/Sv/CD1 genetic background
displayed retinal degeneration, but these were only the
proportion of the mouse colony that were hypopigmented and
presumed to be predominantly CD1, a strain associated with
poor vision [23]. Subsequent breeding to create isogenic strain
backgrounds will make analysis more comparable, and this
process has now been completed for both the Cln3 knock-out
mice by production of inbred 129/Sv lines [57], and C57BL/6J
congenic lines [32,55].
In terms of neuropathology, the Cln3 (ex1–6 replacement)
knock-out mouse is the best characterized but, as discussed
below, similar work has now begun in the knock-in mouse [58].
Despite a mild degree of retinal decline [59], of all the NCL
models, the relative preservation of the retina appears to be
unique to Cln3 (ex1–6 replacement) knock-out mice [19,55].
Loss of retinal neurons and visual function are much more
obvious in the other NCL animal models, as tested by
behavioural or electrophysiological methods. Nevertheless,
Cln3 (ex1–6 replacement) knock-out mice do exhibit effects
upon optic nerve myelination and axon density by 1 year of age
[60], that are preceded by a deficiency in anterograde transport
along the optic nerve and a significant loss of visual relay
neurons in the dorsal lateral geniculate nucleus [61]. These
recent data emphasize that visual defects in JNCL may arise
outside the retina, findings that have significant implications for
the targeting of therapeutic approaches to counter this important
clinical feature.
A range of cellular defects are apparent in Cln3-deficient
cells derived from the knock-in mouse. Primary neuron cultures
derived from the mouse were conditionally immortalised to
make a cerebellar ‘neuronal precursor’ cell model that showed a
Cln3-related storage phenotype, defects in the endocytic
pathway and the transport and processing of cathepsin D, and
a disturbance of mitochondrial morphology and function [62].
Additional work in Cln3-deficient primary cerebellar cultures
and cerebellar slice cultures, derived from Cln3 (ex1–6
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vulnerability to AMPA-type excitatory glutamate receptor-
mediated toxicity, which might be linked to JNCL-related motor
deficits seen in patients [63].
8. Cathepsin deficient mutant mice—models for both
congenital and late-onset NCL?
Cathepsin D and cathepsin F knock-out mouse models exist
which each exhibit an NCL phenotype and it has been proposed
that deficiency of these catalytic lysosome hydrolases leads to
similar neurodegenerative processes [18,24,64].
Cathepsin D is the major aspartic protease of the lysosome
compartment, functioning to catalyze hydrolysis of proteins for
degradation and turnover [18]. In the cathepsin D knock-out
mouse, enzyme activity is completely abolished by gene
targeting of an insertion mutation to disrupt exon 4 of the
Ctsd gene [18]. This is well established as an NCL model with
accumulation of NCL-type autofluorescent storage material in
cells [64]. The storage inclusions have the appearance of INCL-
type granular osmiophilic deposits (GRODs) or lamellar
membranes, and are immunopositive for mitochondrial ATP
synthase subunit c.
A series of human NCL cases with mutations in the human
cathepsin D gene, CTSD, have recently been reported [65].
Depending on the mutation that is present in CTSD this results
in either a congenital form of NCL associated with microceph-
aly, or a later onset disorder. The congential form within one
family with several affected children is associated with a
homozygous nucleotide duplication c.764dupA that creates a
premature stop codon resulting in a stable but enzymatically
inactive mutant protein when transiently expressed in cell
culture [63]. The delayed onset form is associated with the
missense mutation F229I which has significant residual
enzymatic activity [65].
Cathepsin D-deficient sheep also exist which have a severe
neurodegenerative phenotype from birth and an early death
associated with acute brain atrophy, and this model has been
named the ‘congenital ovine NCL’ model [67,68]. The sheep
model carries a naturally-occurring missense mutation in
cathepsin D which again results in an enzymatically inactive
but stable protein [67]. The sheep exhibit a GROD-type storage
disorder, but no accumulation of mitochondrial ATP synthase
subunit c, a difference from the mouse which may be connected
to the specific mutations involved [69]. The storage material in
cathepsin D-deficient sheep did however contain high levels of
saposins A and D, which are associated with GROD-type INCL
storage [67]. Additional fly [3] and dog [70] CTSD-deficient
models exist which also display NCL-like traits.
Ctsd−/− knock-out mice have a very aggressive neurological
disorder, but unlike the other mouse models of classical human
NCL described above, these symptoms are not restricted to the
CNS since several visceral organs are also grossly affected
[18]. These mice develop normally until the age of two weeks
when growth ceases and there is a rapid onset of often severe
seizures and blindness. Mice survive only until an average age
of 26 days, often dying as a result of seizure-inducedrespiratory arrest, but also from reduced feeding ability
associated with dramatic atrophy of the intestinal mucosa,
thymus and spleen [18,64]. Neuropathology in the Ctsd−/−
mouse CNS has been studied in more detail recently, and
prominent involvement of the thalamus and of microglia is
apparent [64,71].
Alongside the granular storage material, Ctsd-deficient
neurons in the brain accumulate progressively higher levels
of autophagic structures with age, suggesting an involvement
of the autophagic pathway in neuronal cell death [64].
Autophagy has also been proposed as a neurodegenerative
mechanism in Cln3-deficient neurons [53], and further
extended as a possible pathogenic mechanism underlying all
the NCLs [25].
The newest putative mouse model for human NCL has a
deficiency in the less well-studied cathepsin F, a lysosomal
cysteine protease [72]. A mutation in the Ctsf gene was made by
targeted replacement of exons 7–9 with an insertion cassette,
which abolishes Ctsf protein expression [24]. Initial examina-
tion of Ctsf−/− mice shows widespread progressive accumula-
tion of autofluorescent storage inclusions in the CNS, however
these mice also exhibit some unique features that are not typical
of NCL disease. Ctsf−/− mice have a much later onset phenotype
than Ctsd−/− mice, and in fact on a similar mixed 129/Sv/
C57BL/6J strain background, the lifespan of Ctsf−/− mice is
longer than that of the Cln3 (ex1–6 replacement) knock-out
mouse model of juvenile NCL [57]. However, unlike Cln3-
deficient mice, Ctsf−/− mice exhibit striking visible neurological
manifestations prior to death, from the age of 12–16 months,
and some of the more severely affected animals had
spontaneous seizures [24]. The disease course of Ctsf−/− mice
suggests that these mice are most likely to be a candidate for
late-onset NCL, although mutational analysis of 13 adult-onset
NCL patients did not reveal any mutations in the human CTSF
gene [24].
Further analysis of the Ctsf−/− storage material was also
intriguing, revealing an NCL-type lamellar structure of stacked
membranes, but these were associated with ‘lipid droplet’
structures that were more numerous than is usual for NCL-
related ceroid-lipofuscin. Moreover, similarly to Ctsd−/− mice,
no increase in mitochondrial ATP synthase subunit c was
apparent in Ctsf−/− mice even by 19 months of age. Since
mitochondrial ATP synthase subunit c is a major component of
the storage material of all the later onset (non-GROD storing)
NCL forms, this suggests that the storage material in Ctsf−/−
mice may be distinct from any other NCL form, with a unique
mechanism of origin. Although detailed neuropathological data
are not yet available from Ctsf−/− mice, initial evidence suggests
a pathological profile that is clearly distinct from Ctsd−/−
knock-out mice, being confined to the CNS without significant
visceral involvement.
The cathepsins represent a new class of NCL protein and
recent studies in cathepsin B- and L-double deficient mice
suggest these two enzymes are of interest for NCL analysis due
to similarities in the pathogenesis [25]. Cathepsin A deficiency
is associated with the lysosomal storage disorder galactosiali-
dosis which has various neurodegenerative features [73]. It is
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cathepsin D could also give rise to cases of human NCL.
9. Other mice with NCL-like phenotypes
Mice with genetically engineered mutations in the Ppt2 gene
and two CLC chloride channel genes, Clcn3 and Clcn7, have
also been suggested as putative NCL mouse models, although
these genes have not yet been directly linked to human NCL.
The creation and pathological phenotype of mice with a null
mutation in palmitoyl protein thioesterase 2 (Ppt2) has been
described previously [16,31,53]. Ppt2 is a lysosomal thioester-
ase homologous to Ppt1, but it has a distinct substrate specificity
[74,75] and mice deficient in these enzymes have distinct
features. Like Ctsd−/− knock-out mice, but unlike Ppt1 knock-
out mice, Ppt2−/− mice have major visceral manifestations
affecting the bone marrow, spleen and pancreas, in addition to
some typical NCL-like features in the CNS. The neurodegen-
erative and neurological phenotype of Ppt2−/− mice features
NCL-type autofluorescent storage and neuronal loss, with
motor deficits, seizures and a premature death with only 10%
survival by 17 months, but it is of later onset than that of Ppt1
mice. Moreover, the storage material in Ppt2−/− mice is unlike
that of Ppt1 mice, being membraneous rather than granular
[16,31].
Mice that have null mutations in two chloride channels of
the CLC family, CLC-3 and CLC-7, have also been reported
to have an NCL-like phenotype with progressive neurodegen-
eration in the CNS accompanied by the intracellular
accumulation of autofluorescent storage material [26–29].
However, the CNS of these mice has not yet been
characterized in detail and neither displays a typical NCL-
like phenotype; in fact, certain important differences are
apparent, raising the possibility that these mice may not
actually represent models of NCL.
Three Clcn3−/− knock-out mice have been created and these
show general neurological features including blindness, growth
retardation and increased mortality associated with marked
brain atrophy [26–28,53] although the most severe neuronal
loss occurs preferentially in the hippocampus which is unlike
any form of NCL. Indeed, the hippocampal formation is almost
totally lost in Clcn3−/− mice, which is consistent with the high
expression of ClC-3 in this structure [26]. A Clcn7−/− knock-
out mouse model has also been created [29]. The initial finding
of an NCL-like disorder in Clcn3−/− mouse brains [28], has
been disputed in a study which looked at both Clcn3−/− and
Clcn7−/− mice simultaneously and found that an NCL-like
cellular phenotype was only associated with loss of ClC-7 , and
that there was in fact no lysosomal storage phenotype in
Clcn3−/− mice [30]. The Clcn7−/− mice were shown to have
NCL-like granular autofluorescent deposits in CNS and other
cells, and these contained both mitochondrial ATP synthase
subunit c and saposin D [30]. Clcn7−/− mice also displayed
general neurological features including growth retardation and
retinal degeneration. Uniquely these mice also display severe
osteopetrosis which has never been associated with any form of
NCL.Neurodegeneration in Clcn7−/− mice is obvious from the early
postnatal period and is again most marked in the hippocampus,
particularly in CA3 which is completely lost [30]. It remains to be
resolved if the phenotypes of these mice are really similar to the
NCLs or whether they arise from defects in unrelated endocytic
proteins. Both chloride channels are localized to particular
subclasses of vesicles in cells and although their function is not
yet clear they both play a role in intravesicular acidification. ClC-3
is located in endosomes and synaptic vesicles while ClC-7 is the
only CLC that has been localized predominantly to the lysosomes,
as well to endosomes [76].
Mutations in the human CLCN7 gene cause malignant
infantile osteopetrosis, a heterogeneous disorder that is associ-
ated in some cases with NCL-like autofluorescent lipofuscin
accumulation and neurological features caused by brain and
retinal atrophy [29,77,78]. It appears that only loss-of-function
CLCN7 mutations, which account for some recessive cases of
osteopetrosis, are linked to the neurodegenerative features, since
dominant mutations inCLCN7 cause most of the inherited forms
of osteopetrosis which are less severe and not generally
associated with neurodegenerative features [29,77–79].
Studies on the Clcn7 protein have also raised interest in
Ostm1, a protein it interacts with in osteoclast cells, due to
similarities between Clcn7 and Ostm1 mutant phenotypes [80].
Deficiency of Ostm1 in the grey-lethal mouse and in human
patients carrying OSTM1 mutations causes severe osteopetrosis
and a lysosomal storage disorder [80–82] similar to that
associated with Clcn7-deficiency. It will be important to
investigate the detailed phenotype of CLC-7 deficiency in
patients and mice to determine the possible relevance of these
mutations to NCL pathogenesis.
10. Common themes in NCL pathogenesis
Each of the existing mouse models of NCL that exist exhibit
phenotypes that resemble key features of the human disorder
(Table 1) [15–17,19,21–23,46,53,64,83]. These include a range
of clinically relevant behavioural and pathological changes and
reveal each of these models to exhibit a progressive neurode-
generative disorder. Ultimately mouse models of NCL will
prove an invaluable resource for testing therapeutic interven-
tions as initial work has indicated [32,34,35,42]. However, the
major focus of current research is to obtain detailed molecular,
proteomic, behavioural and neuropathological landmarks of
disease progression in each model. The great advantage of these
models is the ability to obtain these data relatively simply at
different stages of disease progression, making it possible to
define the precise sequence of events during pathogenesis.
These on-going studies have revealed several novel and
unexpected features of NCL pathogenesis, and suggest that
several long-held concepts about disease may now need to be
revised.
11. Selective nature of neuronal loss
Neuronal loss is widespread at autopsy in all forms of human
NCL [83,84], but is particularly devastating in infantile NCL
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with graded effects upon neuronal survival in different subfields
of the hippocampus and different cortical regions [87–90], and
in a variety of subcortical structures [53,84]. Investigating the
patterns of neuronal loss in sheep and mouse models of different
forms of NCL emphasizes the selective nature of neuronal
vulnerability [53]. Indeed, by studying when neuronal loss is
first apparent in these models it is clear that certain neuron
populations exhibit remarkable vulnerability, or indeed resis-
tance, to the effects of disease.
Among the first neuron populations to be implicated as
vulnerable in mouse models of NCL were GABAergic
interneurons in the cortex and hippocampus of Cln8mnd mice
[46]. These findings have since been replicated in mouse models
of INCL, LINCL, JNCL and multiple variant forms of LINCL
[21,22,33,57,58]. The dysfunction of hippocampal GABAergic
interneurons in Ctsd−/− mice appears to be due to reduced
GABA levels associated with reduced lysosomal degradation of
GAD67, the enzyme that is normally involved in the synthesis of
GABA, such that lysosomal accumulation of degraded forms of
this enzyme occurs [91]. Interneuron populations in mouse
models of NCL exhibit a graded vulnerability dependent on
location, and which calcium binding protein or neuropeptide(s)
is usually expressed by subsets of these neurons.
Although quantitative data from human autopsy material is
currently limited in extent, data from mouse and higher
eukaryotic species are generally in agreement with these
qualitative findings. For example, the patterns of interneuron
vulnerability evident in mouse models of NCL are closely
mirrored by interneuron populations immunoreactive for these
markers in human autopsy material [89]. Indeed, calretinin
immunoreactive interneurons are consistently more resistant to
the effects of disease in murine, human and ovine NCL
[33,53,89], whereas their somatostatin or parvalbumin positive
counterparts display greater vulnerability that is maintained
across species boundaries [33,46,50].
However, it is also apparent that other factors beyond simple
phenotypic identity play a significant influence upon neuronal
vulnerability in multiple forms of NCL. For example, sensory
regions of cortex are consistently more vulnerable than regions
serving motor or limbic functions [33,51], exhibiting greater
degrees of cortical thinning and loss of lamina IV granule, lamina
V pyramidal neurons or GABAergic interneurons. Moreover, as
discussed below, there is also good evidence that these changes in
sensory cortex occur subsequent to the loss of corresponding
sensory relay neurons within the thalamus (e.g., [58,61]). As such
it appears that cellular location rather than purely phenotypic
identity is the major determinant of neuron survival, with data
emerging from mouse and sheep models to suggest that examples
of selective neuron vulnerability are to be found in multiple regions
of the CNS in each form of the disorder [53], consistent with
findings in human autopsy material [89].
12. Early effects upon thalamocortical neuron survival
The relative vulnerability of neurons in different cortical
laminae is nowwell documented in mouse models [33,57,58], asare effects upon cerebellar Purkinje neurons [16,17]. However,
by examining the progressive staging of neuron loss and, in
particular, glial activation, it is clear that the thalamus is an
important and early pathological target in multiple forms of
NCL. Prominent silver staining of degenerating neurons and
their cortical projections is apparent in Tpp1-deficient mice [17]
and a pronounced loss of thalamic neurons relaying somatosen-
sory and pain information to the cortex is evident in Cln3-
deficient mouse models of juvenile NCL ([58] and Pontikis et
al., unpublished observations), a feature which appears to be
replicated in Ppt1-deficient mice [133]. This loss of thalamic
relay neurons is also evident for other sensory modalities, most
notably within the visual system and occurs manymonths before
their target cortical neurons are lost [61,133]. Indeed, the
suggestion that thalamic neuron loss may be the basis of visual
deficits in juvenile NCL clearly has important implications for
the targeting of therapeutic approaches. Data of this type also
raise the intriguing possibility that the selective effects upon
sensory vs. motor cortex [33,57,58] may occur secondary to loss
of afferent sensory input from the thalamus.
13. Early glial responses in disease progression
The reason for the particular vulnerability of thalamic
relay neurons remains unclear, but the localized activation of
astrocytes and microglia also occurs within the same
individual thalamic nuclei [33,58]. Indeed, although reactive
changes are widespread at the end stages of the disease [33],
multiple lines of evidence now point to localized astrocytosis
early in disease progression. This phenomenon was first
described in Cln3 (ex1–6 replacement) knock-out mice [58],
with a low level glial activation preceding overt neuron loss
by many months. Similar data are now available from the
South Hampshire sheep model of CLN6, with the distribu-
tion of activated astrocytes and microglia accurately predict-
ing the distribution of subsequent neuron loss, although this
is not evident for many months after birth [51]. Indeed,
reactive changes are evident surprisingly early in this sheep
model, being first evident in the white matter as early as the
second trimester of pregnancy, before spreading into the
cortical grey matter around the time of birth [92].
It will be important to determine whether such early reactive
changes represent a protective response or part of the
degenerative cascade leading to neuron death. Evidence for
similar early and localized reactive responses is now also
emerging from mouse models (Fig. 1), with an early astrocytic
response, followed by neuronal loss and a second wave of
microglial activation at the later stages of disease progression
[133]. Nevertheless, the precise mechanisms by which neuronal
injury and/or dysfunction may initiate this proposed patholog-
ical cascade remain largely unknown.
Intriguingly, both microglia and astrocytes fail to show
morphological evidence of complete activation in either Cln3
knock-out or Cln3 knock-in mice [57,58], suggesting that these
cell types may be incapable of mounting an appropriate
response in these JNCL mice. Nevertheless, the localized
nature of both neuron loss and glial activation in multiple mouse
Fig. 1. Successive neurodegenerative and inflammatory events in NCL disease progression.
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important role in pathogenesis, although their precise nature
remains unclear.
One particularly significant form of interaction between
astrocytes and neurons occurs at the synapse, with these
characteristically reactive cell types exerting a powerful effect on
synaptic strength and efficacy [93–95]. Indeed, far from simply
acting in response to changes in the extracellular environment,
emerging evidence suggests that astrocytes play more dynamic and
interactive roles within the CNS than previously considered [94–
96]. The early and localized activation of astrocytes in multiple
forms of NCL [51,57,92], together with evidence for abnormal
glial responses in JNCL [57,58], both hint that this relationship
between astrocytes and neurons may be compromised in the
early stages of pathogenesis.
Furthermore, several lines of evidence point towards the
involvement of synapses early in disease progression.
Neurons cultured from Ppt1 (ex 9 insertion) knock-out mice
exhibit a reduced synaptic vesicle pool size [36]; the
colocalization of PPT1 or CLN3 with presynaptic markers
is lost when INCL or JNCL mutant proteins are expressed
[97,98]; there is a presynaptic accumulation of excess
glutamate in Cln3 (ex1–6 replacement) knock-out mice [99]
and preliminary data reveal a complex series of up-regulation
or down-regulation of presynaptic markers in multiple forms
of NCL. It remains to be seen whether such synaptic reor-
ganization represents an early sign of neuronal dysfunction, or
perhaps is a determinant of neuronal vulnerability. Indeed, it
will be particularly interesting to determine if there is any
functional relationship between these events at the synapse
and the localized activation of astrocytes early in disease
progression.
14. Autoimmune responses in NCL pathogenesis
The concept of altered neuroimmune responses in JNCL was
taken a step further by the discovery of autoantibodies toglutamate acid decarboxylase (GAD65) in both human and
murine JNCL [99,100]. These GAD65 autoantibodies appear to
be functional as there are reduced levels of GAD65 activity and
elevated levels of glutamate in Cln3 (ex1–6 replacement)
knock-out mice [99], findings that have been replicated and
extended by metabolomic profiling of these mice [101].
However, it is now apparent that this autoimmune response is
not exclusively to GAD65, but that multiple brain-directed
autoantibodies are raised in individuals with JNCL [102].
Indeed, GAD65 autoantibodies appear to contribute relatively
little to JNCL serum immunoreactivity [102] and are not present
in other forms of NCL. However, immunoglobulins are
deposited within the JNCL CNS and appear to be generated
systemically, gaining access to the CNS via a size selective
breach in the blood–brain-barrier [134]. Nevertheless, it
remains to be seen whether these immunoglobulins are
pathogenic, and this will be an important question to resolve
before attempting to modulate the immune system in a clinical
setting.
15. The influence of strain background and mutation type
in comparative studies of NCL mouse models
The NCLs are disorders which have traditionally been
grouped together on the basis of their comparable clinical and
cellular features, and more recently due to evidence for a shared
molecular basis in certain related cellular pathways. However,
underlying these broad similarities there are in fact several
levels of genetic and clinical heterogeneity that may have
fundamental influences upon NCL pathogenesis.
There is a spectrum of disease features associated with each
of the known NCL genes, with evidence for genotype–
phenotype correlations in each form of the disorder. For
example, PPT1-deficiency can no longer be regarded as simply
an infantile-onset disease, since there are later onset NCL cases
associated with distinct PPT1 mutations [103,104]. The same is
also true for other forms of NCL [105], for example in CLN3
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disease course [39]. In CLN8 patients, mutations prevalent in
Northern and Southern Europe have a clearly distinct clinical
disease course [47,52]. Until recently no atypical phenotypes
had been identified for CLN5, or Finnish variant late-infantile
NCL, CLN5 [43], but a new CLN5 mutation associated with a
later age of onset has recently been determined, although the
effect of this mutation has not yet been studied [106].
It is also clear that additional genetic or environmental
effects play a role in determining the features of NCL disease,
since marked variability in clinical course exists even if exactly
the same mutations have been inherited amongst affected
families [39,107–109]. Indeed, variations between affected
siblings that have inherited identical mutations are also well
recognised. This variation highlights the likely influence of the
genetic environment that exists in individuals, and could also
reflect non-genetic factors and environmental influences.
The mechanisms governing NCL phenotypes that involve
other ‘modifier’ genes or non-genetic factors, are of great
potential interest since their interactions with disease causing
genes may offer insights towards novel therapeutic approaches
[110]. Animal models provide a tool for investigating these
events and evidence suggests that NCL models show disease
variations akin to that seen in NCL patients. Not only do
striking differences occur between species, as discussed above
for the Ctsd-deficient mice and sheep models, but also amongst
the more easily cross-comparable NCL mouse models.
Clear differences in phenotype can occur according to what
mouse strain background a particular mutation has been bred
onto. Indeed, it is possible to map and characterize modifier loci
if mice with distinct testable phenotypes can be identified, and
analysis of mice in a controlled environment reduces the
influence of non-genetic factors. Efforts have already been
made to map modifiers of the phenotype in Cln8mnd mice which
display altered disease severity on different genetic back-
grounds [111]. Cln2-deficient mice also demonstrate strain
background-related phenotypic differences [17], and further
breeding schemes are likely to reveal the same phenomenon in
other NCL mice. At present, direct comparisons between
laboratories and different conditions of animal husbandry must
be tentative, especially when the range of analytical techniques
that have been used is extensive. In future, better studies will
arise with breeding of all the mouse NCL mutations on to the
same inbred or congenic strain background, and preferably
when mice are co-housed in a similar controlled environment.
Such studies conducted in comparatively housed NCL mice
with the same strain background have already started to emerge
[55,112].
Amongst the NCL mouse models a variety of mutations have
been created which could influence gene function differently,
and this is also important to note in any comparison of mutants.
Whether these different mutations completely abolish NCL
gene function is a critical issue that has not yet been resolved in
all instances. This issue is complicated by the lack of adequate
antibodies to detect endogenous protein and provide definitive
proof that the mutant protein is absent in Cln3−/−, Cln5−/−,
Cln8mnd or Cln6nclf mutant mice. In contrast, the absence ofenzyme activity in Ctsd, Ctsf, Ppt1, Tpp1 mouse models could
be relatively simply established via an appropriate assay [16–
18,22,24]. Gene targeting strategies may also leave multiple
residual mRNA species present, as is evident in the two mouse
models of JNCL that focussed on disruption of exons 7–8 of
Cln3 [20,23]. Although Cln3 (ex1–6 replacement) knock-out
mice do not express detectable Cln3 protein in western blots
[60], Cln3 knock-in mice display residual expression of Cln3
protein, leading to speculation that some protein function could
be retained in this model [23]. This residual expression of Cln3
could produce a different effect on cell homeostasis than
complete absence of the Cln3 protein would in a complete
knock-out. Similarly, Cln5 mRNA species are not fully
abolished in the Cln5−/− knock-out mouse, and the currently
available antibodies do not allow definitive proof that the
mutant protein is absent from these mice [21].
16. Genomic, proteomic and metabolomic perturbations in
NCL mouse models
NCL mouse models have proved valuable for high through-
put post-genomic molecular analyses, making use of tissues that
would not be available from patients. The application of DNA
microarray analysis makes simultaneous investigation of
multiple pathways and processes possible, and has revealed
alterations in the expression of genes involved in a number of
cellular processes in both Ppt1 knock-out mice, and the Cln5−/−
and Cln3 (ex1–6 replacement) knock-out mice [21,22,113–
115]. Transcript profiling has so far focussed on early
expression in the presymptomatic cerebral cortex [21],
cerebellum [113], retina [115], and whole brain [114], or in
end-stage cortex [22]. A great number of expression changes
(up- and down-regulation) were determined from these
analyses, some of which tended to become more marked with
age. There were significant perturbations in steady-state
expression levels for genes involved in a number of common
pathological pathways including neuronal and synaptic func-
tion, inflammation, myelin integrity and neuronal degeneration.
There were also indications of disturbances in oxidative stress
and energy metabolism pathways, and subcellular defects in
endocytic and synaptic functions and lipid metabolism.
Expression profiling through microarrays has the potential to
be a powerful technique for determining cellular changes in the
NCLs, but brain tissue is highly heterogeneous and interpreta-
tion of microarray data is complex. As such, it can be difficult to
distinguish between primary deficits and secondary down-
stream features. To date there is little overlap between the gene
sets characterized in each NCL mouse model, which can be
viewed as encouraging for the specificity of the changes.
However, a range of ages and tissues were used and comparison
between microarray studies is hampered by differences in
techniques and data normalisation. Studies in the same
laboratory are perhaps most comparable, and these have been
useful in indicating specific differences in expression patterns
between brain and eye tissue in the Cln3 (ex1–6 replacement)
knock-out mouse, indicating eye-specific disturbances of
mitochondrial energy production [115]. However, there are
Fig. 2. Large scale screening in Zebrafish.
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NCL subtype; the differences between the two Ppt1-deficient
mice may be explained by the underlying mutations, but are
also likely greatly influenced by the difference in the disease
stage that was sampled and differences in technical analysis
[22,114].
Some confirmation of NCL mouse model microarray data by
other methods has been initiated, and this has started to allow a
molecular dissection of the underlying neurodegenerative
pathways and to reveal specific molecular targets. Because of
the heterogeneity of the CNS, it is likely that sampling of
subsets of cells, and being able to specifically sample diseased
cells of choice will enhance the information obtained.
Specialized methods of cell isolation and RNA amplification,
for example the incorporation of laser capture microdissection,
provide exciting potential for refined methods and even single
cell analysis [116].
Proteomic techniques have also been used on tissues and
cells from NCL mouse models, for example to analyse
perturbations in lysosomal enzyme activities including those
of NCL enzymes [19,21,62,64,117] and amino acid levels
[118]. Most recently a survey of lysosome enzyme activities
indicated no major differences in Cln5−/− mice for activity of
five hydrolases including Ppt1 and Tpp1, except for a slight
increase in Tpp1 activity [21]. Perturbations in the mannose-6-
phosphate modified lysosomal hydrolases have previously been
recorded for various human NCL forms [119] and certain other
NCL mice [19,23,117]. NCL mouse models provide a valuable
source of material for analysis by higher throughput protein
[120] and metabolomic techniques [101]. Further such analyses
are currently in progress and will allow for global profiling of
protein changes that result from loss of NCL protein functions.
17. Zebrafish models of NCL
Although mouse models of NCL are providing significant
clues to the underlying biological basis of the disease, such
studies in mice can be relatively slow, laborious and expensive
to perform. Fortunately, other small vertebrate species are
available to study the consequences of gene mutation and the
zebrafish is now increasingly becoming the vertebrate of choice
both for modelling diseases and for drug discovery [121].
Zebrafish have significant advantages over mice in producing
hundreds of externally fertilised eggs that develop in vitro into
optically transparent embryos. Furthermore, the generation time
is comparatively short with fish reaching adulthood in 3 to 4
months, and the costs of keeping fish are significantly lower
than mice. Therefore many experiments can be performed on a
single clutch and live manipulations and observations can be
carried out from the earliest stages of development. These
considerations make zebrafish particularly suitable for the
systematic large-scale screening of banks of small molecules
and drugs in multiwell plates for potential therapeutic agents.
An added advantage is that any toxicity of these compounds is
also apparent at a much earlier stage in the drug discovery
process (Fig. 2). Taken together with the ability to perform
relatively simple, yet powerful, analyses of genetic interactions,it is clear that zebrafish represent an attractive option for
addressing key aspects of NCL pathogenesis and assessing
novel therapeutic approaches.
18. Assessing gene function in zebrafish
As an experimental organism, zebrafish can be exploited in
many ways (reviewed in [122] and Fig. 3). Zebrafish are
amenable to a variety of simple gain- and loss-of-function
techniques. Gain-of-function experiments, in which a gene
product is ectopically expressed, reveal what that gene product is
capable of doing. Such ectopic expression in the whole embryo is
usually performed by RNA injection, which has an effect for the
limited period of a couple of days in the embryo. Alternatively,
RNA can be introduced at particular times and locations either by
electroporation or via an inducible expression system.
In particular, forward mutagenesis screens have been used to
produce fish with randomly induced mutations. These can either
be screened for NCL phenotypes or for mutations in genes
known to cause NCL [123,124], Alternatively modified
antisense oligonucleotides, or morpholinos, can be designed
to knock down the function of genes that cause NCL (reviewed
in [123]). Although morpholinos tend to be effective only for a
few days in the embryo, this method is nevertheless powerful
for demonstrating the consequences of gene knock down and
for providing ‘proof of principle’ for modelling a specific gene
defect in zebrafish.
When designing therapeutic strategies, it is important to
know whether a gene product acts cell autonomously or not.
Chimeric zebrafish can be relatively simply generated by tissue
transplantation to answer this question. This approach can also
reveal in which tissues a gene product is required which a
significant issue in the NCLs since gene products that are
Fig. 3. Analysis of gene function in Zebrafish.
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upon mutation.
19. Exploring genetic interactions in zebrafish
Epistatic analyses, to reveal whether gene products function
in the same or different pathways, are also relatively easy to
explore in zebrafish, either by cross-breeding to produce
mutants with multiple gene deficits or by combining loss-of-
function and gain-of-function techniques. For example, if
injecting a specific RNA rescues a mutant phenotype, that
RNA must function downstream of the mutant gene. Such
analyses are invaluable in determining whether proteins
function in the same or different pathways. Significantly,
very little is known about which pathways the NCL gene
products might normally function in, especially whether or not
they may function in the same pathway. Indeed, an epistatic
approach in zebrafish may be the key to understanding why
mutations in so many diverse genes cause grossly similar NCL
phenotypes.
Zebrafish also provide an excellent system for studying
protein localization in vivo in real time using fluorescently
tagged proteins expressed in live animals, rather than in cell
culture [125]. This approach provides information about where
a protein may act within the cell and if this varies between
different cell types. In addition, many transgenics expressing
fluorescent proteins in specific cells are available (reviewed in
[126]) and will be useful for assessing phenotypes and the
subcellular localization of proteins in zebrafish models of
NCL.20. Towards zebrafish models of NCL
An important consideration in choosing an organism to
model disease is how close its biology resembles that of
humans. The nervous system of zebrafish is well characterized
[127,128] and is considered suitable for comparison to
humans [129]. Indeed, there are many aspects of nervous
system development and function that are now being
modelled in zebrafish [130]. In the case of vision, zebrafish
are more similar to humans than rodents, making zebrafish
particularly effective for modelling retinal degeneration
[131,132], suggesting that this species represents a particu-
larly useful model for studying retinal phenotypes in the
NCLs.
Critically, zebrafish have homologues of many of the
genes mutated in different forms of human NCL. Examination
of the zebrafish Ensembl database (http://www.ensembl.org/
Danio_rerio/index.html) and ZFIN (http://www.zfin.org)
reveals one homologue each of CLN1/PPT1, CLN2/TPP1,
CLN5, CLN6 and CSTD, and Blast homology searches suggest
that genes mutated in other forms of NCL are also present.
Potentially, all forms of NCL could be modelled in zebrafish
by recovering and examining the appropriate mutants. Mor-
pholino experiments to knock down gene function in zebrafish
embryos are already underway to prove that the NCLs can
indeed be modelled in this species, thereby fuelling the search
for stable mutations in these genes in zebrafish. Clearly
zebrafish are a powerful tool for genetics of this species make
it the ideal vertebrate for addressing basic questions about the
genes mutated in each form of NCL.
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A panel of ten mouse mutants is now available that model all
the cloned NCL gene disorders CTSD, CLN1, CLN2, CLN3,
CLN5, CLN6 and CLN8. All the NCL mouse models have
progressive neurodegenerative phenotypes that closely resem-
ble the pathology of human NCL, and their utility is clear from
the many experimental techniques that have already been put to
use in the study of NCL disease. These mice have the advantage
of enabling a previously impossible detailed analysis of disease
progression, and characterization of NCL mice has already
indicated some novel features in NCL pathogenesis (Fig. 4).
It is now evident that neurodegeneration within the NCL
CNS is not global, but is remarkably localized in all models
examined so far. Although the cortex is clearly affected in all
NCL mice, this only occurs relatively late in disease prog-
ression, with a prominent loss of thalamic relay neurons evident
before significant neuron loss in the cortex. Moreover, irres-
pective of location, neuronal loss in multiple forms of NCL is
invariably preceded by astrocytic activation. At the cellular
level, it is clear that neuronal cell death may involve not just
apoptotic pathways, but also incorporates an autophagic mode
of programmed cell death. It is also apparent that the NCLs are
likely to have a significant developmental component, with
pathological effects evident far earlier than suspected. Although
the precise nature of neuronal injury remains unclear, the
presynaptic compartment is emerging as an important focus for
the disease, with effects at the synapse perhaps mediated
partially through glia.
The ability to model the range of NCL disorders and other
neurological phenotypes in mice has also revealed that there is a
larger spectrum of NCL-related diseases than previously
imagined. Indeed, several important new NCL-like mouse
models with potentially significant NCL-related phenotypes
have now been described. These include mouse models with
mutations in cathepsin F, CLC-3 and CLC-7 chloride channels,
and PPT2. In addition a new model, the grey lethal mouse thatFig. 4. Key events and thcarries an engineered mutation in Ostm1, exhibits an NCL-like
phenotype, highlighting the potential significance of interactions
between Ostm1 and ClC-7. With the exception of cathepsin D
knock-out mice, clinical symptoms in the mice that model a
known NCL subtype are confined to the CNS as is the case for
NCL patients. However, with the exception of Ctsf−/− mice, all
the NCL-like mice that do not yet have a human correlate exhibit
significant visceral involvement of symptoms.
Discovery of these similar phenotypes has introduced new
research groups to the NCL field and has started to revolutionise
some of the long-standing perceptions about these diseases, for
example taking the emphasis away from ultrastructural infor-
mation and towards new molecular mechanistic hypotheses. It
is known from genetic studies in NCL families that additional
human NCL genes remain to be identified, and newly identified
mice with NCL-like phenotypes may provide potential new
NCL candidate genes.
Investigation of the pathogeneses of neurodegenerative
diseases and the NCLs using mouse models and other
approaches has significantly progressed over the past few
years. It is anticipated that therapies based on more detailed
understanding of the disease mechanisms will ultimately be
identified, with mouse models providing highly useful tools for
the rapid assessment of which therapies should be pursued.
Accumulating experimental evidence highlights the importance
of a common strain background for meaningful comparative
analysis between NCL mouse models, and the first studies of
multiple NCL mice on a uniform background are emerging
[55,112].
While mice provide a key model system, they also have
some limitations for analysis. The zebrafish has certain distinct
advantages as a small vertebrate model, with a short generation
time, large brood size, increasingly well-understood anatomy,
physiology and genetics, and sophisticated methods for
molecular analysis, including large scale screening of thera-
peutic compounds. Zebrafish are ideally suited to answering
questions of developmental biology and for exploring basiceir staging in NCL.
886 J.D. Cooper et al. / Biochimica et Biophysica Acta 1762 (2006) 873–889genetics such as epistatic gene interactions. Although homol-
ogous recombination is not possible in this species, experimen-
tal techniques have now been developed to create mutations for
disease analysis. Since zebrafish have homologs of most if not
all the NCL genes, a variety of approaches are currently
underway to map the expression of these NCL genes and
perform mutational analysis to create model systems for further
NCL research.
In the context of approaches in invertebrates and large
animal models, a wide range of model organisms will soon be
available for studying the biology of each form of NCL. As
discussed in this review and elsewhere in this issue, each model
system has its inherent advantages and disadvantages. However,
the advent of these model systems will provide an invaluable
resource for researchers working to understand the mechanistic
basis of these profoundly disabling disorders.
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